AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma

MONDAY, April 8, 2024-- For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the...